Skip to main content

Advertisement

Log in

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Dimerization is essential for activity of human epidermal growth factor receptors (HER1/EGFR, HER2/ErbB2, HER3/ErbB3, and ErbB4) and mediates intracellular signaling events leading to cancer cell proliferation, survival, and resistance to therapy. HER2 is the preferred dimerization partner. Activation of HER signaling pathways may be blocked by inhibition of dimer formation using a monoclonal antibody (MAb) directed against the dimerization domain of HER2. The murine MAb 2C4 that specifically binds the HER2 dimerization domain was cloned as a chimeric antibody, humanized using a computer-generated model to guide framework substitutions, and variants were tested as Fabs. Pharmacokinetics and toxicology were evaluated in rodents and cynomolgus monkeys. Cloning the variable domains of MAb 2C4 into a vector containing human kappa and CH1 domains allowed construction of a mouse-human chimeric Fab. DNA sequencing of the chimeric clone permitted identification of CDR residues. The full-length IgG1 of variant F-10 was equivalent in binding to chimeric IgG1 and was designated pertuzumab (rhuMAb 2C4; Omnitarg). Pertuzumab pharmacokinetics was best described by a two-compartment model with a distribution phase of <1 day, terminal half-life of ~10 days, and volume of distribution of ~40 mL/kg that approximates serum volume. With the exception of diarrhea, pertuzumab was generally well tolerated in cynomolgus monkeys. Pertuzumab, a recombinant humanized IgG1 MAb, is the first of a new class of agents known as HER dimerization inhibitors. Inhibition of HER dimerization may be an effective anticancer strategy in tumors with either normal or elevated expression of HER2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Agus DB, Akita RW, Fox WD, Lofgren JA, Higgins B, Maiese K, Scher HI, Sliwkowski MX (2000) A potential role for activated HER-2 in prostate cancer. Semin Oncol 27:76–83

    PubMed  CAS  Google Scholar 

  2. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and tumor growth. Cancer Cell 2:127–137

    Article  PubMed  CAS  Google Scholar 

  3. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23:2534–2543

    Article  PubMed  CAS  Google Scholar 

  4. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, Di Fiore PP, Kraus MH (1995) Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813–1821

    PubMed  CAS  Google Scholar 

  5. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12:541–552

    Article  PubMed  CAS  Google Scholar 

  6. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285–4289

    Article  PubMed  CAS  Google Scholar 

  7. Chen X, Yeung TK, Wang Z (2000) Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Commun 277:757–763

    Article  PubMed  CAS  Google Scholar 

  8. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, Leahy DJ (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756–760

    Article  PubMed  CAS  Google Scholar 

  9. Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff S, Padlan EA, Davies D, Tulip WR, Colman PM, Spinelli S, Alzari PM, Poljak RJ (1989) Conformations of immunoglobulin hypervariable regions. Nature 342:877–883

    Article  PubMed  CAS  Google Scholar 

  10. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J Jr, Chien KR, Lee KF (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8:459–465

    Article  PubMed  CAS  Google Scholar 

  11. Dunnett CW (1964) New tables for multiple comparisons with a control. Biometrics 20:482–491

    Article  Google Scholar 

  12. Eigenbrot C, Gonzalez T, Mayeda J, Carter P, Werther W, Hotaling T, Fox J, Kessler J (1994) X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD18 antibody: structural indications of the key role of VH residues 59 to 65. Proteins 18:49–62

    Article  PubMed  CAS  Google Scholar 

  13. Eigenbrot C, Randal M, Presta L, Carter P, Kossiakoff AA (1993) X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. J Mol Biol 229:969–995

    Article  PubMed  CAS  Google Scholar 

  14. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A (1990) Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 50:1550–1558

    PubMed  CAS  Google Scholar 

  15. Fernando NH, Hurwitz HI (2003) Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 30(Suppl 6):39–50

    Article  PubMed  CAS  Google Scholar 

  16. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX (2004) Insights into ErbB signaling. Cancer Cell 5:317–328

    Article  PubMed  CAS  Google Scholar 

  17. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Kofler M, Jorissen RN, Nice EC, Burgess AW, Ward CW (2003) The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 11:495–505

    Article  PubMed  CAS  Google Scholar 

  18. Gerstner RB, Carter P, Lowman HB (2002) Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody. J Mol Biol 321:851–862

    Article  PubMed  CAS  Google Scholar 

  19. Gorman CM, Gies DR, McCray G (1990) Transient production of proteins using an adenovirus transformed cell line. DNA Prot Eng Tech 2:3–10

    Google Scholar 

  20. Graham FL, Smiley J, Russell WC, Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59–74

    Article  PubMed  CAS  Google Scholar 

  21. Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647–1655

    Article  PubMed  CAS  Google Scholar 

  22. Harris KA, Washington CB, Lieberman G, Lu JF, Mass R, Bruno R (2002) A population pharmacokinetic (PK) model for trastuzumab (Herceptin) and implications for clinical dosing. Proc Am Soc Clin Oncol 21 (abstr 488)

  23. Holbro T, Civenni G, Hynes NE (2003) The ErbB receptors and their role in cancer progression. Exp Cell Res 284:99–110

    Article  PubMed  CAS  Google Scholar 

  24. Ings RMJ (1990) Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 20:120–131

    Article  Google Scholar 

  25. Jones JT, Akita RW, Sliwkowski MX (1999) Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 447:227–231

    Article  PubMed  CAS  Google Scholar 

  26. Kabat EA, Wu TT, Perry H, Gottesmann KS, Foeller C (1991) Sequences of proteins of immunological interest, 5th edn. Public Health Service, National Institutes of Health Bethesda, MD

    Google Scholar 

  27. Keely SJ, Uribe JM, Barrett KE (1998) Carbachol stimulates transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in T84 cells. Implications for carbachol-stimulated chloride secretion. J Biol Chem 273:27111–27117

    Article  PubMed  CAS  Google Scholar 

  28. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158

    Article  PubMed  CAS  Google Scholar 

  29. Kunkel TA (1985) Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci USA 82:488–492

    Article  PubMed  CAS  Google Scholar 

  30. Lee H, Akita RW, Sliwkowski MX, Maihle NJ (2001) A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. Cancer Res 61:4467–4473

    PubMed  CAS  Google Scholar 

  31. Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, Ghahramani P (2003) Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21:3965–3971

    Article  PubMed  CAS  Google Scholar 

  32. Liu J, Kern JA (2002) Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation. Am J Resp Cell Mol Biol 27:306–313

    CAS  Google Scholar 

  33. Malik MA, Totpal K, Balter I, Sliwkowski MX, Pelletier N, Reich M, Crocker L, Friess T, Bauer S, Fiebig HH, Allison DE (2003) Dose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models. Proc Am Assoc Cancer Res 44:150 (abstr 773)

    Google Scholar 

  34. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN (2001) Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120:1713–1719

    Article  PubMed  CAS  Google Scholar 

  35. Mendoza N, Phillips GL, Silva J, Schwall R, Wickramasinghe D (2002) Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res 62:5485–5488

    PubMed  CAS  Google Scholar 

  36. Negro A, Brar BK, Lee KF (2004) Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 59:1–12

    Article  PubMed  CAS  Google Scholar 

  37. Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, Hynes NE (1998) ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol 18:5042–5051

    PubMed  CAS  Google Scholar 

  38. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238–3247

    Article  PubMed  CAS  Google Scholar 

  39. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y (1996) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452–2467

    PubMed  CAS  Google Scholar 

  40. Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593–4599

    PubMed  CAS  Google Scholar 

  41. Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM (1993) Humanization of an antibody directed against IgE. J Immunol 151:2623–2632

    PubMed  CAS  Google Scholar 

  42. Schroff RW, Foon KAA, Beatty SSM, Odham RK, Morgan AC Jr (1985) Human anti-murine immunoglobulin response in patients receiving monoclonal antibody therapy. Cancer Res 45:879–885

    PubMed  CAS  Google Scholar 

  43. Sias PE, Kotts CE, Vetterlein D, Shepard M, Wong WL (1990) ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. J Immunol Methods 132:73–80

    Article  PubMed  CAS  Google Scholar 

  44. Suter TM, Cook-Bruns N, Barton C (2004) Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 13:173–183

    Article  PubMed  CAS  Google Scholar 

  45. Totpal K, Balter I, Akita R, Bargiacchi F, Phillips GL, Sliwkowski MX (2003) Targeting ErbB2/HER2’s role as a coreceptor with rhuMAb2C4 inhibits Erb/HER ligand-dependent signaling and proliferation of ovarian tumor cell lines. Proc Am Assoc Cancer Res 44:151 (abstr 776)

    Google Scholar 

  46. Tramontano A, Chothia C, Lesk AM (1990) Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. J Mol Biol 215:175–182

    Article  PubMed  CAS  Google Scholar 

  47. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y (1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276–5287

    PubMed  CAS  Google Scholar 

  48. Vajdos FF, Adams CW, Breece TN, Presta LG, de Vos AM, Sidhu SS (2002) Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol 320:415–428

    Article  PubMed  CAS  Google Scholar 

  49. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A (1995) Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14:4267–4275

    PubMed  CAS  Google Scholar 

  50. Werther WA, Gonzalez TN, O’Conner SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG (1996) Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 157:4986–4995

    PubMed  CAS  Google Scholar 

  51. Winer BJ (1971) Analysis of covariance. In: Statistical principles in experimental design, 2nd edn. McGraw-Hill, New York, pp 752–812

  52. Winer BJ (1971) Design and analysis of single-factor experiments. In: Statistical principles in experimental design. 2nd edn. McGraw-Hill, New York, pp 149–260

  53. Xiang J, Sha Y, Jia Z, Prasad L, Delbaere LT (1995) Framework residues 71 and 93 of the chimeric B72.3 antibody are major determinants of the conformation of the heavy-chain hypervariable. J Mol Biol 253:385–390

    Article  PubMed  CAS  Google Scholar 

  54. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137

    Article  PubMed  CAS  Google Scholar 

  55. Yen L, Benlimame N, Nie ZR, Xiao D, Wang T, Al Moustafa AE, Esumi H, Milanini J, Hynes NE, Pages G, Alaoui-Jamali MA (2002) Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell 13:4029–4044

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors gratefully acknowledge the important contributions of Tim Breece and Charlie Schmelzer (for protein purification), Henry Lowman (for BIAcore assays), Mubashira A. Malik (for assistance with PK assays) and the Oligosynthesis and DNA Sequencing Groups at Genentech Inc.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Camellia W. Adams.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adams, C.W., Allison, D.E., Flagella, K. et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55, 717–727 (2006). https://doi.org/10.1007/s00262-005-0058-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-005-0058-x

Keywords

Navigation